ClinicalTrials.gg
CompletedNCT03945292SEQUOIAUpdated Nov 4, 2025Results posted

Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)

A Phase 2 interventional study of Fazisiran Injection and Placebo in Alpha 1-Antitrypsin Deficiency, sponsored by Arrowhead Pharmaceuticals. Completed at 21 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-04.

Sponsored by Arrowhead Pharmaceuticals · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States — 17 open to participants now, 22 under way, 5 of them phase 3. alpha 1-Antitrypsin Deficiency · United States.

Enrollment
21st of 55
40 · median 30
Started
2019
with 3 others
Phase 2
20 of 81
none open now
Registered
57th of 81
by date

Among the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, this one is the 21st largest by enrollment of the 55 interventional ones that give a count, is one of 4 that started in 2019, is one of 20 in phase 2, and was the 57th registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

17 of the 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in alpha 1-Antitrypsin Deficiency with a site in United States, or all of them as a file.
02

Study summary

The purpose of AROAAT2001 (SEQUOIA) is to evaluate the safety, efficacy and tolerability of multiple doses of the investigational product, Fazirsiran Injection, administered subcutaneously to participants with alpha-1 antitrypsin deficiency (AATD).

Read the detailed description

Participants will be enrolled to receive multiple subcutaneous injections of Fazirsiran Injection (also referred to as TAK-999 Injection or ARO-AAT Injection) or placebo. Eligible participants will require a pre-dose biopsy completed as part of the study within the screening window. However, any participant with a biopsy result within 1 year of screening showing no fibrosis does not require a pre-dose biopsy. Only participants who have liver fibrosis will undergo a post-dose biopsy and may continue treatment in an open-label phase.

03

Conditions studied

  • Alpha 1-Antitrypsin Deficiency
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of AATD
  • Liver at Screening indicating liver fibrosis (score less than F4); a patient with no fibrosis may participate based on a previous biopsy conducted within one year
  • Women of must have a negative pregnancy test, cannot be breastfeeding, and must be willing to use
  • Willing to provide written and to comply with study requirements
  • Non-smoker for at least 1 year
  • No abnormal finding of clinical relevance at Screening

Exclusion criteria

Exclusion Criteria:

  • health concerns other than AATD
  • Previous diagnosis or diagnosis at Screening of definitive liver cirrhosis
  • Previous lung or liver transplant due to AATD
  • Regular use of alcohol within one month prior to Screening
  • Use of an agent or device within 30 days prior to dosing or current participation in an investigational study involving therapeutic intervention
  • Use of illicit drugs within 1 year prior to Screening

NOTE: additional inclusion/exclusion criteria may apply, per protocol

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Fazirsiran 25 mg DB/200 mg OL

    Double-blind (DB) Period: Participants with no fibrosis: Administered on Day 1 and Week 4. Participants with fibrosis: Administered on Day 1, Week 4, and Week 16, then every 12 weeks up to 18 total doses. Open-label (OL) Period: Participants with fibrosis at Screening who received double-blind (DB) fazirsiran 25 mg and who completed the post-dose liver biopsy at Week 48 (or Week 72 or Week 96) entered the open-label phase and received fazirsiran 200 mg every 12 weeks for the duration of the study.

    Drug: Fazisiran Injection

  • Experimental
    Fazirsiran 100 mg DB/200 mg OL

    DB Period: Participants with no fibrosis: Fazirsiran 100 mg administered on Day 1 and Week 4. Participants with fibrosis: Fazirsiran 100 mg administered on Day 1, Week 4, and Week 16, then every 12 weeks up to 18 total doses. OL Period: Participants with fibrosis at Screening who received double-blind (DB) fazirsiran 100 mg and who completed the post-dose liver biopsy at Week 48 (or Week 72 or Week 96) entered the open-label phase and received fazirsiran 200 mg every 12 weeks for the duration of the study.

    Drug: Fazisiran Injection

  • Experimental
    Fazirsiran 200 mg DB/200 mg OL

    DB Period: Participants with no fibrosis: Fazirsiran 200 mg administered on Day 1 and Week 4. Participants with fibrosis: Fazirsiran 200 mg administered on Day 1, Week 4, and Week 16, then every 12 weeks up to 18 total doses. OL Period: Participants with fibrosis at Screening who received double-blind (DB) fazirsiran 200 mg and who completed the post-dose liver biopsy at Week 48 (or Week 72 or Week 96) entered the open-label phase and received fazirsiran 200 mg every 12 weeks for the duration of the study

    Drug: Fazisiran Injection

  • Placebo comparator
    Placebo DB / Fazirsiran 200 mg OL

    DB Period: Participants with no fibrosis: Placebo administered on Day 1 and Week 4. Participants with fibrosis: Placebo administered on Day 1, Week 4, and Week 16, then every 12 weeks up to 18 total doses. OL Period: Participants with fibrosis at Screening who received double-blind (DB) placebo and who completed the post-dose liver biopsy at Week 48 (or Week 72 or Week 96) entered the open-label phase and received fazirsiran 200 mg every 12 weeks for the duration of the study.

    Drug: Fazisiran Injection · Other: Placebo

Interventions

  • DrugFazirsiranStudies of FazirsiranFazirsiran pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    solution for subcutaneous (sc) injection

    Also known as: ARO-AAT Injection, TAK-999 Injection

  • OtherPlacebo

    sterile normal saline (0.9% NaCl), calculated to match active comparator, for sc injection

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Serum Z-Alpha-1 Antitrypsin (Z-AAT) at Week 16

    Time frame: Baseline, Week 16 (+/- 2 weeks)

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Double-Blind Phase

    An adverse event (AE) is any untoward medical occurrence, which does not necessarily have to have a causal relationship with this treatment. A serious adverse event (SAE) is an AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important event or reaction. TEAEs/TESAEs are defined as those AEs that first occurred or worsened in severity following dose administration through end of study (EOS) or Early Termination or first dose of open-label phase fazirsiran.

    Time frame: Double Blind Phase (up to Week 48): dose administration through end of study (EOS) or Early Termination or first dose of open-label phase fazirsiran.

  2. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Open-Label Phase

    An adverse event (AE) is any untoward medical occurrence, which does not necessarily have to have a causal relationship with this treatment. A serious adverse event (SAE) is an AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important event or reaction. TEAEs/TESAEs are defined as those AEs that first occurred or worsened in severity following dose administration through end of study (EOS) or Early Termination or first dose of open-label phase fazirsiran.

    Time frame: From dose administration of the first dose of open-label phase fazirsiran through EOS or Early Termination (up to Week 196).

  3. Absolute Change From Baseline in Total Liver Z-AAT (Insoluble + Soluble) Protein at Post-dose Biopsy for Participants With Fibrosis

    Post-dose biopsy includes all post-dose biopsy collected at Week 48 or Week 72 or Week 96.

    Time frame: Baseline, Week 48 (+/- 2 weeks), or Week 72 (+/- 4 weeks), or Week 96 (+/- 4 weeks)

  4. Percent Change From Baseline in Total Liver Z-AAT (Insoluble + Soluble) Protein at Post-dose Biopsy for Participants With Fibrosis

    Post-dose biopsy includes all post-dose biopsy collected at Week 48 or Week 72 or Week 96.

    Time frame: Baseline, Week 48 (+/- 2 weeks), or Week 72 (+/- 4 weeks), or Week 96 (+/- 4 weeks)

  5. Absolute Change From Baseline in Liver Z-AAT Soluble Protein at Post-dose Biopsy for Participants With Fibrosis

    Post-dose biopsy includes all post-dose biopsy collected at Week 48 or Week 72 or Week 96.

    Time frame: Baseline, Week 48 (+/- 2 weeks), or Week 72 (+/- 4 weeks), or Week 96 (+/- 4 weeks)

  6. Percent Change From Baseline in Liver Z-AAT Soluble Protein at Post-dose Biopsy for Participants With Fibrosis

    Post-dose biopsy includes all post-dose biopsy collected at Week 48 or Week 72 or Week 96.

    Time frame: Baseline, Week 48 (+/- 2 weeks), or Week 72 (+/- 4 weeks), or Week 96 (+/- 4 weeks)

  7. Absolute Change From Baseline in Liver Z-AAT Insoluble Protein at Post-dose Biopsy for Participants With Fibrosis

    Post-dose biopsy includes all post-dose biopsy collected at Week 48 or Week 72 or Week 96.

    Time frame: Baseline, Week 48 (+/- 2 weeks), or Week 72 (+/- 4 weeks), or Week 96 (+/- 4 weeks)

  8. Percent Change From Baseline in Liver Z-AAT Insoluble Protein at Post-dose Biopsy for Participants With Fibrosis

    Post-dose biopsy includes all post-dose biopsy collected at Week 48 or Week 72 or Week 96.

    Time frame: Baseline, Week 48 (+/- 2 weeks), or Week 72 (+/- 4 weeks), or Week 96 (+/- 4 weeks)

  9. Absolute Change From Baseline in Liver Function Tests: Alanine Aminotransferase (ALT) at Week 16 and Over Time Through End of Study (EOS)

    PDLB=post-dose liver biopsy

    Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)

  10. Percent Change From Baseline in Liver Function Tests: ALT at Week 16 and Over Time Through EOS

    PDLB=post-dose liver biopsy

    Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)

  11. Absolute Change From Baseline in Liver Function Tests: Aspartate Aminotransferase (AST) at Week 16 and Over Time Through EOS

    PDLB=post-dose liver biopsy

    Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)

  12. Percent Change From Baseline in Liver Function Tests: AST at Week 16 and Over Time Through EOS

    PDLB=post-dose liver biopsy

    Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)

  13. Absolute Change From Baseline in Liver Function Tests: Alkaline Phosphatase (ALP) at Week 16 and Over Time Through EOS

    PDLB=post-dose liver biopsy

    Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)

  14. Percent Change From Baseline in Liver Function Tests: ALP at Week 16 and Over Time Through EOS

    PDLB=post-dose liver biopsy

    Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)

  15. Absolute Change From Baseline in Liver Function Tests: Gamma Glutamyl Transferase (GGT) at Week 16 and Over Time Through EOS

    PDLB=post-dose liver biopsy

    Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124,136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)

  16. Percent Change From Baseline in Liver Function Tests: GGT at Week 16 and Over Time Through EOS

    PDLB=post-dose liver biopsy

    Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)

  17. Absolute Change From Baseline in Liver Function Tests: Total Bilirubin at Week 16 and Over Time Through EOS

    PDLB=post-dose liver biopsy

    Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124,136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)

  18. Percent Change From Baseline in Liver Function Tests: Total Bilirubin at Week 16 and Over Time Through EOS

    PDLB=post-dose liver biopsy

    Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)

  19. Absolute Change From Baseline in Liver Function Tests: Direct Bilirubin at Week 16 and Over Time Through EOS

    PDLB=post-dose liver biopsy

    Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)

  20. Percent Change From Baseline in Liver Function Tests: Direct Bilirubin at Week 16 and Over Time Through EOS

    PDLB=post-dose liver biopsy

    Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)

  21. Absolute Change From Baseline in Liver Function Tests: Prothrombin International Normalized Ratio at Week 16 and Over Time Through EOS

    PDLB=post-dose liver biopsy

    Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)

  22. Percent Change From Baseline in Liver Function Tests: Prothrombin International Normalized Ratio at Week 16 and Over Time Through EOS

    PDLB=post-dose liver biopsy

    Time frame: Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)

  23. Absolute Change in Serum Z-AAT Over Time Through EOS

    PDLB=post-dose liver biopsy

    Time frame: Baseline, Weeks 2, 4, 6, 16, 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)

  24. Percent Change in Serum Z-AAT Over Time Through EOS

    PDLB=post-dose liver biopsy

    Time frame: Baseline, Weeks 2, 4, 6, 16, 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)

  25. Pharmacokinetics (PK): ARO-AAT Plasma Concentration Summary for the Double-Blind Phase

    Time frame: Fazirsiran participants without fibrosis: Pre-dose, 1 hour, 2 hour, 24 hours post-dose on Day 1 (+/- 1 day). Fazirsiran participants with fibrosis: Pre-dose, 1 hour, 2 hours, 24 hours post-dose on Day 1 and Week 16 (+/- 1 day).

  26. Number of Participants Positive for Anti-Drug Antibodies to Fazirsiran

    PDLB=post-dose liver biopsy

    Time frame: Baseline, Weeks 4, 16, 28, 40, 48, 52, 64, 76, 88, 96, 100, 112, 124, 136, 148 or Early Termination (up to 148 weeks)

  27. Percentage of Participants With Shifts From Baseline in METAVIR Fibrosis Stage at Post-Dose Biopsy for Participants With Fibrosis

    The METAVIR scoring system is a system used to assess the extent of inflammation and fibrosis by histopathological evaluation in a liver biopsy. The stage represents the amount of fibrosis or scarring: 0= no fibrosis; 1=portal fibrosis without septa; 2=portal fibrosis with few septa; 3=numerous septa without cirrhosis; 4=cirrhosis. A higher score indicates a worse condition.

    Time frame: Baseline, Post-dose at Weeks 48 (+/- 2 weeks) or Week 72 (+/- 4 weeks) or Week 96 (+/- 4 weeks)

07

Results

Posted Dec 30, 2024

Participant flow

Double-Blind (DB) Period: Weeks 0 to 48
Participant flow — Double-Blind (DB) Period: Weeks 0 to 48
MilestoneFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlaceboFazirsiran 25 mg DB/200 mg OLFazirsiran 100 mg DB/200 mg OLFazirsiran 200 mg DB/200 mg OLPlacebo DB / Fazirsiran 200 mg OL
Started989140000
Completed887140000
Not completed10200000
Withdrew: Withdrawal by subject10100000
Withdrew: Adverse event00100000
Open-Label (OL) Period: Weeks 48 to 196
Participant flow — Open-Label (OL) Period: Weeks 48 to 196
MilestoneFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlaceboFazirsiran 25 mg DB/200 mg OLFazirsiran 100 mg DB/200 mg OLFazirsiran 200 mg DB/200 mg OLPlacebo DB / Fazirsiran 200 mg OL
Started00004559
Completed00004558
Not completed00000001
Withdrew: Adverse event00000001

Outcome measures

PrimaryPercent Change From Baseline in Serum Z-Alpha-1 Antitrypsin (Z-AAT) at Week 16
Time frame:
Baseline, Week 16 (+/- 2 weeks)
Reported as:
Least squares mean · percentage change
Percent Change From Baseline in Serum Z-Alpha-1 Antitrypsin (Z-AAT) at Week 16
percentage changeFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
Percent Change From Baseline in Serum Z-Alpha-1 Antitrypsin (Z-AAT) at Week 16-62.17 ± 4.279-85.39 ± 4.634-92.93 ± 4.3414.64 ± 3.211
Statistical analysis
  • Fazirsiran 25 mg vs Placebo · Mixed model repeated measures (MMRM) · p = < 0.0001 (From a mixed model with repeated measures, including fixed effects for treatment, week, treatment-by-week interaction, presence of metabolic syndrome, presence of NAFLD or NASH, baseline serum Z-AAT as covariate, and subject as a random effect.) · Difference: -66.81 · 95% CI -77.18 to -56.45NAFLD=non-alcoholic fatty liver disease; NSH=non-alcoholic steatohepatitis
  • Fazirsiran 100 mg vs Placebo · MMRM · p = < 0.0001 (From a mixed model with repeated measures, including fixed effects for treatment, week, treatment-by-week interaction, presence of metabolic syndrome, presence of NAFLD or NASH, baseline serum Z-AAT as covariate, and subject as a random effect.) · Difference: -90.03 · 95% CI -100.72 to -79.34
  • Fazirsiran 200 mg vs Placebo · MMRM · p = < 0.0001 (From a mixed model with repeated measures, including fixed effects for treatment, week, treatment-by-week interaction, presence of metabolic syndrome, presence of NAFLD or NASH, baseline serum Z-AAT as covariate, and subject as a random effect.) · Difference: -97.57 · 95% CI -108.21 to -86.94
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Double-Blind Phase

An adverse event (AE) is any untoward medical occurrence, which does not necessarily have to have a causal relationship with this treatment. A serious adverse event (SAE) is an AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important event or reaction. TEAEs/TESAEs are defined as those AEs that first occurred or worsened in severity following dose administration through end of study (EOS) or Early Termination or first dose of open-label phase fazirsiran.

Time frame:
Double Blind Phase (up to Week 48): dose administration through end of study (EOS) or Early Termination or first dose of open-label phase fazirsiran.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Double-Blind Phase
ParticipantsFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
TEAEs98914
TESAEs0023
TEAEs Leading to Withdrawal of Study Drug0010
TEAEs Leading to Study Termination0010
TEAEs Leading to Death0000
TEAEs by Worst Severity: Mild3215
TEAEs by Worst Severity: Moderate6666
TEAEs by Worst Severity: Severe0023
TEAEs by Worst Relationship: Not Related7456
TEAEs by Worst Relationship: Possibly Related2318
TEAEs by Worst Relationship: Probably Related0130
TEAEs by Worst Relationship: Possibly or Probably2448
TEAE at Injection Site1122
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Open-Label Phase

An adverse event (AE) is any untoward medical occurrence, which does not necessarily have to have a causal relationship with this treatment. A serious adverse event (SAE) is an AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a medically important event or reaction. TEAEs/TESAEs are defined as those AEs that first occurred or worsened in severity following dose administration through end of study (EOS) or Early Termination or first dose of open-label phase fazirsiran.

Time frame:
From dose administration of the first dose of open-label phase fazirsiran through EOS or Early Termination (up to Week 196).
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in the Open-Label Phase
ParticipantsFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
TEAEs4439
TESAEs1111
TEAEs Leading to Withdrawal of Study Drug0001
TEAEs Leading to Study Termination0001
TEAEs Leading to Death0000
TEAEs by Worst Severity: Mild3207
TEAEs by Worst Severity: Moderate0131
TEAEs by Worst Severity: Severe1101
TEAEs by Worst Relationship: Not Related2037
TEAEs by Worst Relationship: Possibly Related2302
TEAEs by Worst Relationship: Probably Related0100
TEAEs by Worst Relationship: Possibly or Probably2402
TEAE at Injection Site1100
SecondaryAbsolute Change From Baseline in Total Liver Z-AAT (Insoluble + Soluble) Protein at Post-dose Biopsy for Participants With Fibrosis

Post-dose biopsy includes all post-dose biopsy collected at Week 48 or Week 72 or Week 96.

Time frame:
Baseline, Week 48 (+/- 2 weeks), or Week 72 (+/- 4 weeks), or Week 96 (+/- 4 weeks)
Reported as:
Mean · nmol/g
Absolute Change From Baseline in Total Liver Z-AAT (Insoluble + Soluble) Protein at Post-dose Biopsy for Participants With Fibrosis
nmol/gFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
Absolute Change From Baseline in Total Liver Z-AAT (Insoluble + Soluble) Protein at Post-dose Biopsy for Participants With Fibrosis-89.341 ± 94.832-259.892 ± 330.199-29.371 ± 22.867-4.738 ± 57.342
SecondaryPercent Change From Baseline in Total Liver Z-AAT (Insoluble + Soluble) Protein at Post-dose Biopsy for Participants With Fibrosis

Post-dose biopsy includes all post-dose biopsy collected at Week 48 or Week 72 or Week 96.

Time frame:
Baseline, Week 48 (+/- 2 weeks), or Week 72 (+/- 4 weeks), or Week 96 (+/- 4 weeks)
Reported as:
Least squares mean · percentage change
Percent Change From Baseline in Total Liver Z-AAT (Insoluble + Soluble) Protein at Post-dose Biopsy for Participants With Fibrosis
percentage changeFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
Percent Change From Baseline in Total Liver Z-AAT (Insoluble + Soluble) Protein at Post-dose Biopsy for Participants With Fibrosis-86.89 ± 29.658-81.61 ± 29.503-98.16 ± 23.25642.42 ± 21.133
Statistical analysis
  • Fazirsiran 25 mg vs Placebo · ANCOVA · p = 0.0021 (Model based summary statistics are from an analysis of covariance (ANCOVA) model with fixed effect factors treatment group and baseline total liver Z-AAT protein as a covariate.) · Least squares (ls) mean difference: -129.31 · 95% CI -205.52 to -53.11
  • Fazirsiran 100 mg vs Placebo · ANCOVA · p = 0.0035 (Model based summary statistics are from an analysis of covariance (ANCOVA) model with fixed effect factors treatment group and baseline total liver Z-AAT protein as a covariate.) · Ls mean difference: -124.03 · 95% CI -201.9 to -46.15
  • Fazirsiran 200 mg vs Placebo · ANCOVA · p = 0.0002 (Model based summary statistics are from an analysis of covariance (ANCOVA) model with fixed effect factors treatment group and baseline total liver Z-AAT protein as a covariate.) · Ls mean difference: -140.58 · 95% CI -205.27 to -75.89
SecondaryAbsolute Change From Baseline in Liver Z-AAT Soluble Protein at Post-dose Biopsy for Participants With Fibrosis

Post-dose biopsy includes all post-dose biopsy collected at Week 48 or Week 72 or Week 96.

Time frame:
Baseline, Week 48 (+/- 2 weeks), or Week 72 (+/- 4 weeks), or Week 96 (+/- 4 weeks)
Reported as:
Mean · nmol/g
Absolute Change From Baseline in Liver Z-AAT Soluble Protein at Post-dose Biopsy for Participants With Fibrosis
nmol/gFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
Absolute Change From Baseline in Liver Z-AAT Soluble Protein at Post-dose Biopsy for Participants With Fibrosis-20.427 ± 15.042-109.747 ± 135.114-17.418 ± 4.8602.300 ± 12.940
SecondaryPercent Change From Baseline in Liver Z-AAT Soluble Protein at Post-dose Biopsy for Participants With Fibrosis

Post-dose biopsy includes all post-dose biopsy collected at Week 48 or Week 72 or Week 96.

Time frame:
Baseline, Week 48 (+/- 2 weeks), or Week 72 (+/- 4 weeks), or Week 96 (+/- 4 weeks)
Reported as:
Least squares mean · percentage change
Percent Change From Baseline in Liver Z-AAT Soluble Protein at Post-dose Biopsy for Participants With Fibrosis
percentage changeFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
Percent Change From Baseline in Liver Z-AAT Soluble Protein at Post-dose Biopsy for Participants With Fibrosis-75.73 ± 16.645-87.23 ± 17.064-95.71 ± 12.82422.33 ± 11.890
Statistical analysis
  • Fazirsiran 25 mg vs Placebo · ANCOVA · p = 0.0001 (Model based summary statistics are from an analysis of covariance (ANCOVA) model with fixed effect factors treatment group and baseline soluble liver Z-AAT protein as a covariate.) · Ls mean difference: -98.07 · 95% CI -140.53 to -55.6
  • Fazirsiran 100 mg vs Placebo · ANCOVA · p = < 0.0001 (Model based summary statistics are from an analysis of covariance (ANCOVA) model with fixed effect factors treatment group and baseline soluble liver Z-AAT protein as a covariate.) · Ls mean difference: -109.56 · 95% CI -154.81 to -64.32
  • Fazirsiran 200 mg vs Placebo · ANCOVA · p = < 0.0001 (Model based summary statistics are from an analysis of covariance (ANCOVA) model with fixed effect factors treatment group and baseline soluble liver Z-AAT protein as a covariate.) · Ls mean difference: -118.04 · 95% CI -153.95 to -82.12
SecondaryAbsolute Change From Baseline in Liver Z-AAT Insoluble Protein at Post-dose Biopsy for Participants With Fibrosis

Post-dose biopsy includes all post-dose biopsy collected at Week 48 or Week 72 or Week 96.

Time frame:
Baseline, Week 48 (+/- 2 weeks), or Week 72 (+/- 4 weeks), or Week 96 (+/- 4 weeks)
Reported as:
Mean · nmol/g
Absolute Change From Baseline in Liver Z-AAT Insoluble Protein at Post-dose Biopsy for Participants With Fibrosis
nmol/gFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
Absolute Change From Baseline in Liver Z-AAT Insoluble Protein at Post-dose Biopsy for Participants With Fibrosis-68.914 ± 80.725-150.145 ± 196.675-11.953 ± 18.602-7.038 ± 47.041
SecondaryPercent Change From Baseline in Liver Z-AAT Insoluble Protein at Post-dose Biopsy for Participants With Fibrosis

Post-dose biopsy includes all post-dose biopsy collected at Week 48 or Week 72 or Week 96.

Time frame:
Baseline, Week 48 (+/- 2 weeks), or Week 72 (+/- 4 weeks), or Week 96 (+/- 4 weeks)
Reported as:
Least squares mean · percentage change
Percent Change From Baseline in Liver Z-AAT Insoluble Protein at Post-dose Biopsy for Participants With Fibrosis
percentage changeFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
Percent Change From Baseline in Liver Z-AAT Insoluble Protein at Post-dose Biopsy for Participants With Fibrosis-86.36 ± 60.305-72.44 ± 58.358-101.85 ± 47.49591.35 ± 42.750
Statistical analysis
  • Fazirsiran 25 mg vs Placebo · ANCOVA · p = 0.0247 (Model based summary statistics are from an analysis of covariance (ANCOVA) model with fixed effect factors treatment group and baseline insoluble liver Z-AAT protein as a covariate.) · Ls mean difference: -180.7 · 95% CI -335.77 to -25.64
  • Fazirsiran 100 mg vs Placebo · ANCOVA · p = 0.0382 (Model based summary statistics are from an analysis of covariance (ANCOVA) model with fixed effect factors treatment group and baseline insoluble liver Z-AAT protein as a covariate.) · Ls mean difference: -163.79 · 95% CI -317.65 to -9.93
  • Fazirsiran 200 mg vs Placebo · ANCOVA · p = 0.0064 (Model based summary statistics are from an analysis of covariance (ANCOVA) model with fixed effect factors treatment group and baseline insoluble liver Z-AAT protein as a covariate.) · Ls mean difference: -193.2 · 95% CI -325.25 to -61.15
SecondaryAbsolute Change From Baseline in Liver Function Tests: Alanine Aminotransferase (ALT) at Week 16 and Over Time Through End of Study (EOS)

PDLB=post-dose liver biopsy

Time frame:
Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Reported as:
Mean · U/L
Absolute Change From Baseline in Liver Function Tests: Alanine Aminotransferase (ALT) at Week 16 and Over Time Through End of Study (EOS)
U/LFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
Week 16-3.0 ± 9.17-2.4 ± 5.42-8.4 ± 15.881.7 ± 6.60
Week 16 + 24 H-7.3 ± 11.93-3.8 ± 3.59-2.2 ± 2.860.8 ± 5.31
Week 28-10.7 ± 4.57-5.8 ± 9.560.6 ± 6.481.0 ± 6.91
Week 40-4.6 ± 9.07-5.0 ± 8.783.1 ± 9.79-0.1 ± 4.66
PDLB at Week 48-10.5 ± 10.470.0 ± 16.00-2.2 ± 5.313.3 ± 7.71
Week 52-1.5 ± 12.31-6.0 ± 7.3912.3 ± 33.80-0.4 ± 4.44
Week 64-9.8 ± 8.50-14.3 ± 8.88-0.3 ± 8.305.7 ± 15.48
PDLB at Week 72———-6.0 ± NA
Week 76-7.3 ± 3.06-14.8 ± 9.073.5 ± 8.247.7 ± 8.85
Week 88-9.0 ± 3.46-18.5 ± 9.194.8 ± 4.976.2 ± 7.76
PDLB at Week 96—-21.0 ± 5.6612.0 ± NA10.0 ± 12.73
Week 100-9.0 ± 2.83-21.5 ± 9.197.5 ± 7.781.3 ± 9.43
Week 112-8.0 ± NA-18.0 ± 7.078.0 ± 4.24-0.3 ± 6.43
Week 124—-18.0 ± 4.247.0 ± NA5.0 ± 11.53
Week 136——4.0 ± NA8.3 ± 17.90
Week 148——11.0 ± NA4.3 ± 14.98
Week 160———23.0 ± 4.24
Early Termination——-2.0 ± 9.90—
End of Study7.0 ± 16.64-1.0 ± 5.66-0.5 ± 4.95-0.2 ± 5.45
SecondaryPercent Change From Baseline in Liver Function Tests: ALT at Week 16 and Over Time Through EOS

PDLB=post-dose liver biopsy

Time frame:
Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Reported as:
Mean · percentage change
Percent Change From Baseline in Liver Function Tests: ALT at Week 16 and Over Time Through EOS
percentage changeFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
Week 16-9.6 ± 20.1-4.3 ± 19.9-15.3 ± 16.25.8 ± 16.1
Week 16 + 24 H-15.7 ± 24.8-9.7 ± 8.9-10.8 ± 17.60.5 ± 13.3
Week 28-27.4 ± 8.5-12.4 ± 25.12.0 ± 29.36.4 ± 21.9
Week 40-11.2 ± 21.4-13.0 ± 24.04.0 ± 20.02.9 ± 18.3
PDLB at Week 48-21.7 ± 19.1-1.2 ± 38.2-4.8 ± 20.55.9 ± 15.2
Week 52-1.6 ± 32.9-15.2 ± 18.114.5 ± 28.5-1.4 ± 14.8
Week 64-22.3 ± 20.3-33.3 ± 15.54.4 ± 35.811.0 ± 29.3
PDLB at Week 72———-14.3 ± NA
Week 76-20.0 ± 7.0-33.7 ± 16.224.6 ± 43.626.3 ± 34.1
Week 88-24.1 ± 0.0-39.8 ± 15.928.2 ± 32.620.7 ± 28.6
PDLB at Week 96—-45.7 ± 7.560.0 ± NA44.8 ± 58.7
Week 100-31.0 ± 9.8-46.4 ± 15.238.1 ± 38.19.9 ± 24.1
Week 112-27.6 ± NA-38.9 ± 11.341.4 ± 19.23.3 ± 24.7
Week 124—-39.3 ± 5.135.0 ± NA25.2 ± 49.4
Week 136——20.0 ± NA40.1 ± 79.4
Week 148——55.0 ± NA25.5 ± 61.4
Week 160———88.8 ± 3.0
Early Termination——-10.3 ± 65.0—
End of Study14.1 ± 38.7-6.8 ± 34.6-8.4 ± 15.04.7 ± 23.3
SecondaryAbsolute Change From Baseline in Liver Function Tests: Aspartate Aminotransferase (AST) at Week 16 and Over Time Through EOS

PDLB=post-dose liver biopsy

Time frame:
Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Reported as:
Mean · U/L
Absolute Change From Baseline in Liver Function Tests: Aspartate Aminotransferase (AST) at Week 16 and Over Time Through EOS
U/LFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
Week 16-2.9 ± 8.27-0.1 ± 4.021.1 ± 6.100.7 ± 5.23
Week 16 + 24 H-7.7 ± 11.590.0 ± 2.580.3 ± 3.93-0.4 ± 3.81
Week 28-7.4 ± 7.31-1.3 ± 4.6810.2 ± 27.920.1 ± 5.49
Week 40-2.9 ± 10.782.0 ± 17.552.9 ± 8.25-0.9 ± 3.65
PDLB at Week 48-12.0 ± 10.421.7 ± 4.16-1.0 ± 5.221.2 ± 6.40
Week 52-2.1 ± 9.89-0.9 ± 8.466.3 ± 15.92-0.9 ± 2.93
Week 64-8.8 ± 10.24-10.3 ± 10.40-0.7 ± 4.421.9 ± 7.70
PDLB at Week 72———-3.0 ± NA
Week 76-6.3 ± 4.73-10.3 ± 8.853.2 ± 5.787.5 ± 7.20
Week 88-6.7 ± 5.69-16.5 ± 12.023.8 ± 8.294.2 ± 6.57
PDLB at Week 96—-11.0 ± NA2.0 ± NA5.0 ± 5.66
Week 100-7.5 ± 2.12-21.5 ± 13.441.5 ± 2.120.0 ± 4.76
Week 112-10.0 ± NA-19.0 ± 14.140.5 ± 0.71-2.0 ± 7.00
Week 124—-16.5 ± 10.61-1.0 ± NA2.7 ± 9.29
Week 136——-2.0 ± NA6.7 ± 10.60
Week 148——2.0 ± NA1.0 ± 11.14
Week 160———10.5 ± 0.71
Early Termination——-1.5 ± 4.95—
End of Study4.7 ± 8.331.5 ± 6.361.5 ± 9.19-0.2 ± 3.96
SecondaryPercent Change From Baseline in Liver Function Tests: AST at Week 16 and Over Time Through EOS

PDLB=post-dose liver biopsy

Time frame:
Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Reported as:
Mean · percentage change
Percent Change From Baseline in Liver Function Tests: AST at Week 16 and Over Time Through EOS
percentage changeFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
Week 16-8.3 ± 20.02.6 ± 16.43.5 ± 22.52.5 ± 14.3
Week 16 + 24 H-16.9 ± 24.20.4 ± 7.81.5 ± 17.60.1 ± 9.8
Week 28-19.3 ± 19.3-0.9 ± 14.526.8 ± 68.83.2 ± 17.4
Week 40-4.7 ± 26.910.6 ± 43.48.3 ± 21.7-1.0 ± 11.4
PDLB at Week 48-27.1 ± 20.16.0 ± 12.5-2.0 ± 16.23.4 ± 19.2
Week 52-4.1 ± 27.21.9 ± 20.917.3 ± 40.3-2.8 ± 9.7
Week 64-20.5 ± 23.3-21.4 ± 15.4-2.6 ± 16.89.5 ± 21.6
PDLB at Week 72———-5.9 ± NA
Week 76-17.1 ± 12.7-22.2 ± 13.911.9 ± 22.630.3 ± 32.8
Week 88-16.4 ± 10.1-30.6 ± 15.718.1 ± 34.721.1 ± 29.6
PDLB at Week 96—-26.8 ± NA7.4 ± NA31.9 ± 39.8
Week 100-24.6 ± 9.1-40.5 ± 15.85.6 ± 7.95.2 ± 16.3
Week 112-34.5 ± NA-35.1 ± 18.72.5 ± 3.52.8 ± 27.0
Week 124—-31.0 ± 12.8-3.7 ± NA25.6 ± 53.1
Week 136——-7.4 ± NA39.6 ± 70.4
Week 148——7.4 ± NA21.8 ± 56.6
Week 160———55.2 ± 25.7
Early Termination——-7.3 ± 26.9—
End of Study13.7 ± 24.610.5 ± 35.1-2.7 ± 31.50.7 ± 17.1
SecondaryAbsolute Change From Baseline in Liver Function Tests: Alkaline Phosphatase (ALP) at Week 16 and Over Time Through EOS

PDLB=post-dose liver biopsy

Time frame:
Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Reported as:
Mean · U/L
Absolute Change From Baseline in Liver Function Tests: Alkaline Phosphatase (ALP) at Week 16 and Over Time Through EOS
U/LFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
Week 16-2.8 ± 9.98-4.3 ± 6.50-13.8 ± 14.264.9 ± 13.02
Week 16 + 24 H-9.7 ± 8.62-1.0 ± 2.16-11.7 ± 14.833.6 ± 6.62
Week 280.6 ± 12.29-4.9 ± 6.88-8.4 ± 13.530.7 ± 5.51
Week 40-1.1 ± 15.51-7.1 ± 6.36-8.3 ± 11.381.6 ± 7.43
PDLB at Week 48-10.5 ± 16.62-0.3 ± 1.15-2.8 ± 15.691.2 ± 2.56
Week 52-3.0 ± 15.38-7.6 ± 8.26-3.9 ± 9.361.9 ± 6.01
Week 64-8.3 ± 22.23-6.5 ± 8.960.4 ± 15.662.1 ± 9.25
PDLB at Week 72———5.0 ± NA
Week 76-14.0 ± 23.39-9.0 ± 11.580.5 ± 11.506.5 ± 11.33
Week 88-14.7 ± 21.13-16.5 ± 23.333.0 ± 21.258.4 ± 8.02
PDLB at Week 96—-11.5 ± 13.442.0 ± NA7.0 ± 19.80
Week 100-23.0 ± 26.87-11.5 ± 17.68-2.0 ± 2.838.8 ± 12.04
Week 112-4.0 ± NA-6.0 ± 11.31-2.0 ± 4.245.0 ± 13.75
Week 124—-4.0 ± 5.664.0 ± NA4.3 ± 9.24
Week 136——2.0 ± NA7.0 ± 25.16
Week 148——15.0 ± NA11.0 ± 26.46
Week 160———23.0 ± 26.87
Early Termination——-0.5 ± 17.68—
End of Study1.8 ± 10.40-6.0 ± 0.005.0 ± 9.903.4 ± 11.76
SecondaryPercent Change From Baseline in Liver Function Tests: ALP at Week 16 and Over Time Through EOS

PDLB=post-dose liver biopsy

Time frame:
Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Reported as:
Mean · percentage change
Percent Change From Baseline in Liver Function Tests: ALP at Week 16 and Over Time Through EOS
percentage changeFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
Week 16-0.5 ± 12.8-5.6 ± 8.7-17.7 ± 16.05.8 ± 14.7
Week 16 + 24 H-8.9 ± 6.1-1.2 ± 2.8-14.8 ± 16.85.9 ± 10.0
Week 285.5 ± 20.1-6.4 ± 9.3-10.5 ± 16.11.0 ± 7.2
Week 402.0 ± 16.9-9.3 ± 8.2-10.4 ± 14.92.2 ± 10.4
PDLB at Week 48-8.5 ± 13.9-0.4 ± 1.5-3.3 ± 23.51.7 ± 3.7
Week 520.1 ± 17.0-9.7 ± 11.7-4.9 ± 13.52.7 ± 8.3
Week 64-5.6 ± 18.4-8.3 ± 10.8-0.2 ± 22.53.9 ± 11.0
PDLB at Week 72———7.1 ± NA
Week 76-11.2 ± 18.2-11.4 ± 13.50.7 ± 18.18.0 ± 13.3
Week 88-12.5 ± 15.9-19.6 ± 27.83.2 ± 30.310.6 ± 9.5
PDLB at Week 96—-13.9 ± 15.72.9 ± NA7.6 ± 22.6
Week 100-19.4 ± 19.4-13.6 ± 21.2-2.5 ± 3.610.1 ± 13.4
Week 112-5.6 ± NA-6.9 ± 13.8-2.4 ± 5.55.7 ± 15.6
Week 124—-4.8 ± 6.75.8 ± NA4.7 ± 10.5
Week 136——2.9 ± NA6.8 ± 29.3
Week 148——21.7 ± NA11.5 ± 30.8
Week 160———26.0 ± 30.0
Early Termination——4.6 ± 26.1—
End of Study7.8 ± 18.2-7.2 ± 1.87.1 ± 13.95.3 ± 12.3
SecondaryAbsolute Change From Baseline in Liver Function Tests: Gamma Glutamyl Transferase (GGT) at Week 16 and Over Time Through EOS

PDLB=post-dose liver biopsy

Time frame:
Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124,136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Reported as:
Mean · U/L
Absolute Change From Baseline in Liver Function Tests: Gamma Glutamyl Transferase (GGT) at Week 16 and Over Time Through EOS
U/LFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
Week 162.8 ± 11.48-4.3 ± 5.90-9.1 ± 16.067.0 ± 14.88
Week 16 + 24 H-3.7 ± 16.80-4.8 ± 4.35-4.3 ± 4.931.1 ± 4.62
Week 28-3.5 ± 11.99-5.3 ± 5.57-4.1 ± 9.650.6 ± 8.47
Week 405.3 ± 31.24-3.8 ± 9.290.9 ± 16.880.6 ± 7.69
PDLB at Week 48-13.5 ± 23.67-5.3 ± 4.16-5.3 ± 10.17-0.5 ± 10.48
Week 527.3 ± 36.39-4.3 ± 11.136.8 ± 27.791.7 ± 6.64
Week 64-16.0 ± 13.22-13.0 ± 14.142.7 ± 19.049.3 ± 22.13
PDLB at Week 72———-3.0 ± NA
Week 76-20.3 ± 28.36-13.3 ± 15.48-3.3 ± 11.04-0.3 ± 10.19
Week 88-17.0 ± 29.51-19.0 ± 25.462.0 ± 7.817.2 ± 4.97
PDLB at Week 96—-25.5 ± 14.855.0 ± NA3.5 ± 0.71
Week 100-25.0 ± 28.28-24.5 ± 21.926.5 ± 4.95-2.3 ± 14.29
Week 1120.0 ± NA-21.5 ± 9.195.5 ± 4.954.3 ± 10.41
Week 124—-50.4 ± 2.68.0 ± NA1.7 ± 9.61
Week 136——7.0 ± NA5.0 ± 7.55
Week 148——10.0 ± NA-0.3 ± 11.59
Week 160———3.0 ± 4.24
Early Termination——5.0 ± 4.24—
End of Study22.5 ± 45.68-0.5 ± 0.71-19.5 ± 27.580.6 ± 5.59
SecondaryPercent Change From Baseline in Liver Function Tests: GGT at Week 16 and Over Time Through EOS

PDLB=post-dose liver biopsy

Time frame:
Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Reported as:
Mean · percentage change
Percent Change From Baseline in Liver Function Tests: GGT at Week 16 and Over Time Through EOS
percentage changeFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
Week 165.9 ± 18.9-9.7 ± 12.7-14.8 ± 18.513.9 ± 31.0
Week 16 + 24 H0.8 ± 32.2-9.1 ± 8.6-13.2 ± 13.64.7 ± 15.4
Week 28-2.2 ± 21.5-12.0 ± 11.7-3.2 ± 22.26.8 ± 21.5
Week 4014.4 ± 52.4-6.4 ± 18.3-1.7 ± 31.67.4 ± 14.4
PDLB at Week 48-8.9 ± 36.3-13.3 ± 7.2-10.4 ± 30.98.1 ± 17.6
Week 5226.7 ± 69.5-3.5 ± 25.16.2 ± 35.25.1 ± 15.3
Week 64-23.0 ± 6.7-22.8 ± 17.820.7 ± 69.313.1 ± 24.9
PDLB at Week 72———-6.7 ± NA
Week 76-22.2 ± 13.6-23.1 ± 18.9-0.9 ± 38.49.5 ± 13.3
Week 8813.7 ± 21.1-26.8 ± 34.715.6 ± 39.517.9 ± 15.1
PDLB at Week 96—-42.0 ± 11.225.0 ± NA11.9 ± 2.7
Week 100-23.4 ± 11.7-38.0 ± 24.833.8 ± 22.96.1 ± 24.2
Week 1120.0 ± NA-36.5 ± 3.428.4 ± 23.516.0 ± 32.9
Week 124—-50.4 ± 2.640.0 ± NA8.1 ± 28.7
Week 136——35.0 ± NA18.0 ± 23.4
Week 148——50.0 ± NA2.9 ± 33.3
Week 160———10.0 ± 14.1
Early Termination——30.7 ± 32.1—
End of Study39.2 ± 78.5-2.2 ± 3.1-17.1 ± 24.26.7 ± 18.8
SecondaryAbsolute Change From Baseline in Liver Function Tests: Total Bilirubin at Week 16 and Over Time Through EOS

PDLB=post-dose liver biopsy

Time frame:
Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124,136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Reported as:
Mean · mg/dL
Absolute Change From Baseline in Liver Function Tests: Total Bilirubin at Week 16 and Over Time Through EOS
mg/dLFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
Week 160.079 ± 0.1460.098 ± 0.369-0.051 ± 0.241-0.004 ± 0.208
Week 16 + 24 H0.060 ± 0.0750.163 ± 0.456-0.040 ± 0.182-0.118 ± 0.105
Week 280.109 ± 0.1490.171 ± 0.4700.053 ± 0.2300.012 ± 0.272
Week 400.083 ± 0.1150.164 ± 0.4370.017 ± 0.0920.062 ± 0.434
PDLB at Week 480.043 ± 0.109-0.070 ± 0.5940.098 ± 0.252-0.085 ± 0.178
Week 52-0.023 ± 0.2030.129 ± 0.3620.086 ± 0.1650.099 ± 0.230
Week 640.020 ± 0.2100.188 ± 0.2350.006 ± 0.208-0.086 ± 0.188
PDLB at Week 72———-0.420 ± NA
Week 760.110 ± 0.1050.248 ± 0.357-0.043 ± 0.206-0.018 ± 0.198
Week 880.247 ± 0.3750.105 ± 0.0350.002 ± 0.131-0.050 ± 0.131
PDLB at Week 96—0.020 ± 0.1270.170 ± NA0.065 ± 0.035
Week 100-0.040 ± 0.099-0.055 ± 0.1060.090 ± 0.0420.003 ± 0.203
Week 112-0.020 ± NA-0.010 ± 0.2690.100 ± 0.141-0.060 ± 0.249
Week 124—-0.190 ± 0.0710.130 ± NA-0.037 ± 0.085
Week 136——0.100 ± NA0.003 ± 0.185
Week 148——0.070 ± NA-0.087 ± 0.199
Week 160———-0.090 ± 0.028
Early Termination——-0.010 ± 0.014—
End of Study0.170 ± 0.1230.050 ± 0.1130.025 ± 0.2050.154 ± 0.082
SecondaryPercent Change From Baseline in Liver Function Tests: Total Bilirubin at Week 16 and Over Time Through EOS

PDLB=post-dose liver biopsy

Time frame:
Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Reported as:
Mean · percentage change
Percent Change From Baseline in Liver Function Tests: Total Bilirubin at Week 16 and Over Time Through EOS
percentage changeFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
Week 1619.2 ± 38.515.6 ± 41.73.4 ± 44.11.0 ± 28.0
Week 16 + 24 H16.4 ± 19.225.3 ± 49.73.1 ± 33.1-16.3 ± 12.6
Week 2826.7 ± 36.127.8 ± 51.415.8 ± 36.81.3 ± 37.5
Week 4020.6 ± 27.830.2 ± 51.410.0 ± 21.67.8 ± 46.4
PDLB at Week 4811.8 ± 27.810.8 ± 68.236.5 ± 52.2-10.9 ± 29.4
Week 52-8.3 ± 36.627.5 ± 48.825.4 ± 29.415.5 ± 36.4
Week 6410.3 ± 51.028.5 ± 38.010.0 ± 35.7-13.3 ± 28.1
PDLB at Week 72———-60.0 ± NA
Week 7618.1 ± 16.140.1 ± 57.10.3 ± 31.6-1.0 ± 33.2
Week 8838.0 ± 53.713.1 ± 1.75.4 ± 29.3-7.6 ± 21.4
PDLB at Week 96—0.8 ± 15.939.5 ± NA9.2 ± 1.7
Week 100-11.9 ± 25.2-8.6 ± 15.325.1 ± 4.00.4 ± 31.6
Week 112-5.4 ± NA-5.0 ± 35.137.0 ± 52.4-5.8 ± 30.8
Week 124—-23.6 ± 3.930.2 ± NA-5.7 ± 12.4
Week 136——23.3 ± NA4.4 ± 25.2
Week 148——16.3 ± NA-7.6 ± 29.7
Week 160———-13.4 ± 0.9
Early Termination——-2.9 ± 4.2—
End of Study41.8 ± 36.411.5 ± 26.425.0 ± 69.226.8 ± 16.6
SecondaryAbsolute Change From Baseline in Liver Function Tests: Direct Bilirubin at Week 16 and Over Time Through EOS

PDLB=post-dose liver biopsy

Time frame:
Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Reported as:
Mean · mg/dL
Absolute Change From Baseline in Liver Function Tests: Direct Bilirubin at Week 16 and Over Time Through EOS
mg/dLFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
Week 160.016 ± 0.049-0.006 ± 0.0950.005 ± 0.0940.010 ± 0.061
Week 16 + 24 H0.013 ± 0.0290.055 ± 0.157-0.030 ± 0.081-0.028 ± 0.041
Week 280.029 ± 0.0550.039 ± 0.1400.004 ± 0.0620.008 ± 0.073
Week 400.026 ± 0.0500.045 ± 0.160-0.005 ± 0.0630.020 ± 0.125
PDLB at Week 48-0.005 ± 0.041-0.080 ± 0.2100.007 ± 0.087-0.038 ± 0.065
Week 52-0.024 ± 0.0800.034 ± 0.1070.015 ± 0.0520.031 ± 0.058
Week 64-0.008 ± 0.0810.053 ± 0.061-0.007 ± 0.076-0.019 ± 0.043
PDLB at Week 72———-46.2 ± NA
Week 760.027 ± 0.0290.098 ± 0.069-0.033 ± 0.0730.027 ± 0.057
Week 880.053 ± 0.1140.070 ± 0.014-0.007 ± 0.0430.012 ± 0.026
PDLB at Week 96—0.030 ± NA0.080 ± NA0.045 ± 0.035
Week 1000.000 ± 0.0280.010 ± 0.0140.050 ± 0.0280.018 ± 0.052
Week 1120.020 ± NA0.025 ± 0.0490.055 ± 0.0350.007 ± 0.061
Week 124—-0.040 ± 0.0570.070 ± NA0.020 ± 0.035
Week 136——0.030 ± NA0.013 ± 0.046
Week 148——0.050 ± NA-0.003 ± 0.090
Week 160———0.015 ± 0.007
Early Termination——0.005 ± 0.007—
End of Study0.050 ± 0.0600.010 ± 0.0280.028 ± 0.1380.053 ± 0.044
SecondaryPercent Change From Baseline in Liver Function Tests: Direct Bilirubin at Week 16 and Over Time Through EOS

PDLB=post-dose liver biopsy

Time frame:
Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Reported as:
Mean · percentage change
Percent Change From Baseline in Liver Function Tests: Direct Bilirubin at Week 16 and Over Time Through EOS
percentage changeFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
Week 165.9 ± 30.11.5 ± 31.229.1 ± 67.615.1 ± 58.9
Week 16 + 24 H11.0 ± 16.422.4 ± 50.9-0.1 ± 33.0-8.8 ± 17.0
Week 2819.0 ± 28.315.4 ± 37.321.2 ± 61.910.1 ± 44.6
Week 4017.9 ± 27.516.7 ± 44.915.5 ± 47.614.3 ± 50.2
PDLB at Week 482.9 ± 19.5-9.9 ± 63.019.3 ± 48.7-11.9 ± 23.9
Week 52-12.1 ± 34.317.8 ± 35.125.1 ± 47.019.6 ± 38.5
Week 644.4 ± 39.718.9 ± 26.78.2 ± 37.3-8.6 ± 16.7
PDLB at Week 72———-46.2 ± NA
Week 769.9 ± 7.433.4 ± 20.2-5.4 ± 30.011.4 ± 21.5
Week 8818.2 ± 35.024.9 ± 14.0-3.3 ± 30.35.6 ± 12.1
PDLB at Week 96—7.5 ± NA53.3 ± NA17.1 ± 10.0
Week 100-3.8 ± 16.34.3 ± 6.137.0 ± 13.77.5 ± 23.2
Week 11215.4 ± NA5.3 ± 13.746.4 ± 37.34.1 ± 22.5
Week 124—-10.0 ± 14.146.7 ± NA7.7 ± 13.3
Week 136——20.0 ± NA7.2 ± 18.3
Week 148——33.3 ± NA3.4 ± 38.5
Week 160———6.7 ± 4.6
Early Termination——2.4 ± 3.4—
End of Study34.3 ± 45.65.4 ± 14.796.1 ± 185.540.8 ± 46.7
SecondaryAbsolute Change From Baseline in Liver Function Tests: Prothrombin International Normalized Ratio at Week 16 and Over Time Through EOS

PDLB=post-dose liver biopsy

Time frame:
Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Reported as:
Mean · ratio
Absolute Change From Baseline in Liver Function Tests: Prothrombin International Normalized Ratio at Week 16 and Over Time Through EOS
ratioFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
Week 16-0.012 ± 0.054-0.006 ± 0.0930.011 ± 0.0680.055 ± 0.180
Week 16 + 24 H0.047 ± 0.111-0.085 ± 0.093-0.017 ± 0.1170.036 ± 0.104
Week 28-0.054 ± 0.148-0.059 ± 0.109-0.040 ± 0.107-0.014 ± 0.167
Week 40-0.021 ± 0.113-0.024 ± 0.099-0.022 ± 0.1250.034 ± 0.143
PDLB at Week 48-0.038 ± 0.054-0.067 ± 0.150-0.023 ± 0.1210.022 ± 0.048
Week 52-0.094 ± 0.139-0.053 ± 0.057-0.034 ± 0.076-0.002 ± 0.076
Week 64-0.038 ± 0.089-0.100 ± 0.082-0.043 ± 0.1300.012 ± 0.055
PDLB at Week 72———0.040 ± NA
Week 76-0.033 ± 0.049-0.110 ± 0.130-0.065 ± 0.1360.020 ± 0.046
Week 88-0.053 ± 0.040-0.225 ± 0.177-0.004 ± 0.0830.038 ± 0.026
PDLB at Week 96—-0.195 ± 0.1340.090 ± NA0.045 ± 0.078
Week 1000.000 ± 0.014-0.225 ± 0.163-0.020 ± 0.0990.063 ± 0.045
Week 1120.050 ± NA-0.240 ± 0.1840.035 ± 0.0780.047 ± 0.083
Week 124—-0.175 ± 0.2470.050 ± NA0.053 ± 0.021
Week 136——0.070 ± NA0.043 ± 0.032
Week 148——0.080 ± NA0.040 ± 0.026
Week 160———0.070 ± 0.042
Early Termination——0.045 ± 0.092—
End of Study-0.115 ± 0.170-0.045 ± 0.049-0.035 ± 0.021-0.106 ± 0.149
SecondaryPercent Change From Baseline in Liver Function Tests: Prothrombin International Normalized Ratio at Week 16 and Over Time Through EOS

PDLB=post-dose liver biopsy

Time frame:
Baseline, Week 16, Week 16 + 24 hours (H), Weeks 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Reported as:
Mean · percentage change
Percent Change From Baseline in Liver Function Tests: Prothrombin International Normalized Ratio at Week 16 and Over Time Through EOS
percentage changeFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
Week 16-1.0 ± 4.8-0.7 ± 7.71.2 ± 6.42.6 ± 8.6
Week 16 + 24 H4.4 ± 10.3-7.0 ± 6.9-1.0 ± 10.23.5 ± 9.9
Week 28-3.9 ± 11.8-4.9 ± 8.5-3.3 ± 9.11.2 ± 8.7
Week 40-1.2 ± 9.6-1.6 ± 7.8-1.6 ± 11.33.7 ± 13.0
PDLB at Week 48-3.2 ± 4.7-5.5 ± 13.3-1.5 ± 10.32.2 ± 4.8
Week 52-7.7 ± 10.2-4.7 ± 4.9-2.9 ± 6.30.3 ± 6.9
Week 64-3.2 ± 7.9-8.4 ± 7.1-3.2 ± 11.41.3 ± 5.3
PDLB at Week 72———3.9 ± NA
Week 76-2.8 ± 4.0-8.8 ± 9.9-5.3 ± 11.82.0 ± 4.6
Week 88-4.7 ± 3.1-17.9 ± 12.5-0.3 ± 8.03.7 ± 2.4
PDLB at Week 96—-15.6 ± 9.29.0 ± NA4.6 ± 7.8
Week 1000.0 ± 1.4-18.0 ± 11.3-1.8 ± 9.66.2 ± 4.5
Week 1124.9 ± NA-19.1 ± 12.93.5 ± 7.74.7 ± 8.4
Week 124—-13.4 ± 18.95.0 ± NA5.3 ± 2.1
Week 136——7.0 ± NA4.3 ± 3.3
Week 148——8.0 ± NA3.9 ± 2.5
Week 160———7.0 ± 4.3
Early Termination——4.8 ± 9.4—
End of Study-9.1 ± 12.7-4.3 ± 4.9-3.6 ± 2.0-5.8 ± 4.7
SecondaryAbsolute Change in Serum Z-AAT Over Time Through EOS

PDLB=post-dose liver biopsy

Time frame:
Baseline, Weeks 2, 4, 6, 16, 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Reported as:
Mean · μg/mL
Absolute Change in Serum Z-AAT Over Time Through EOS
μg/mLFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
Week 2-125.511 ± 59.955-156.714 ± 58.127-169.044 ± 40.32816.929 ± 37.723
Week 4-146.267 ± 68.511-178.413 ± 58.821-181.389 ± 41.857-0.429 ± 18.826
Week 6-176.100 ± 47.242-192.719 ± 65.087-188.781 ± 43.5397.000 ± 26.712
Week 16-158.650 ± 50.266-185.213 ± 58.059-182.240 ± 45.71010.286 ± 29.374
Week 28-123.288 ± 62.112-174.275 ± 57.293-175.136 ± 52.838-0.500 ± 25.035
Week 40-122.288 ± 70.057-165.763 ± 59.312-164.629 ± 63.8301.429 ± 20.137
PDLB at Week 48-189.850 ± 64.556-150.900 ± 17.521-194.535 ± 51.12814.333 ± 38.754
Week 52-116.188 ± 72.983-157.300 ± 56.023-165.741 ± 64.535-13.643 ± 36.527
Week 64-187.325 ± 94.397-191.150 ± 80.589-190.284 ± 45.0700.333 ± 27.208
PDLB at Week 72———-6.00 ± NA
Week 76-164.067 ± 65.875-189.225 ± 91.259-177.060 ± 49.718-9.500 ± 20.907
Week 88-142.767 ± 89.632-260.200 ± 82.166-186.116 ± 44.539-1.800 ± 28.490
PDLB at Week 96—-271.100 ± 90.793-194.160 ± NA-35.000 ± 15.556
Week 100-204.650 ± 18.597-244.100 ± 91.358-187.650 ± 3.323-60.725 ± 84.824
Week 112-233.000 ± NA-263.100 ± 91.358-182.550 ± 3.182-22.333 ± 22.679
Week 124—-237.650 ± 102.743-183.000 ± NA-26.000 ± 22.271
Week 136——-183.300 ± NA-8.000 ± 22.650
Week 148——-89.1 ± NA9.333 ± 11.719
Week 160———7.500 ± 9.192
Early Termination——-192.240 ± 81.657—
End of Study-42.750 ± 7.089-103.533 ± 3.443-39.000 ± 1.41419.750 ± 30.966
SecondaryPercent Change in Serum Z-AAT Over Time Through EOS

PDLB=post-dose liver biopsy

Time frame:
Baseline, Weeks 2, 4, 6, 16, 28, 40, 48, 52, 64, 72, 76, 88, 96, 100, 112, 124, 136, 148, 160, Early Termination (up to 196 weeks), EOS (up to 208 weeks)
Reported as:
Mean · percentage change
Percent Change in Serum Z-AAT Over Time Through EOS
percentage changeFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
Week 2-50.8 ± 21.9-69.9 ± 11.4-85.5 ± 4.810.0 ± 23.8
Week 4-60.0 ± 24.6-82.2 ± 7.1-91.8 ± 2.50.5 ± 8.7
Week 6-71.9 ± 14.0-88.4 ± 5.0-95.5 ± 1.93.4 ± 11.4
Week 16-62.4 ± 17.0-85.7 ± 7.6-91.9 ± 5.84.3 ± 12.2
Week 28-48.2 ± 20.6-80.6 ± 7.9-87.6 ± 10.40.1 ± 11.2
Week 40-48.3 ± 23.4-76.5 ± 10.5-81.3 ± 18.80.3 ± 9.2
PDLB at Week 48-73.9 ± 16.7-89.2 ± 2.5-93.9 ± 5.08.7 ± 19.0
Week 52-45.9 ± 24.7-73.0 ± 12.9-82.1 ± 20.5-5.3 ± 14.9
Week 64-70.1 ± 23.5-77.6 ± 9.5-92.2 ± 5.72.1 ± 12.3
PDLB at Week 72———-2.4 ± NA
Week 76-71.8 ± 19.6-75.1 ± 9.0-88.8 ± 10.1-2.4 ± 9.3
Week 88-60.1 ± 32.6-77.8 ± 7.2-90.3 ± 6.30.5 ± 11.4
PDLB at Week 96—-80.9 ± 9.1-95.6 ± NA-11.7 ± 4.2
Week 100-82.5 ± 10.1-72.5 ± 11.2-93.8 ± 0.3-21.3 ± 29.6
Week 112-91.7 ± NA-78.4 ± 9.9-91.3 ± 3.5-8.4 ± 9.2
Week 124—-70.1 ± 15.2-90.1 ± NA-9.9 ± 9.1
Week 136——-90.3 ± NA-3.2 ± 8.8
Week 148——-89.1 ± NA3.1 ± 4.1
Week 160———2.4 ± 2.9
Early Termination——-91.7 ± 8.5—
End of Study-18.0 ± 2.7-53.8 ± 6.6-23.4 ± 0.19.1 ± 12.4
SecondaryPharmacokinetics (PK): ARO-AAT Plasma Concentration Summary for the Double-Blind Phase
Time frame:
Fazirsiran participants without fibrosis: Pre-dose, 1 hour, 2 hour, 24 hours post-dose on Day 1 (+/- 1 day). Fazirsiran participants with fibrosis: Pre-dose, 1 hour, 2 hours, 24 hours post-dose on Day 1 and Week 16 (+/- 1 day).
Reported as:
Geometric mean · ng/mL
Pharmacokinetics (PK): ARO-AAT Plasma Concentration Summary for the Double-Blind Phase
ng/mLFazirsiran 25 mg: Participants With No FibrosisFazirsiran 25 mg: Participants With FibrosisFazirsiran 100 mg: Participants With No FibrosisFazirsiran 100 mg: Participants With FibrosisFazirsiran 200 mg: Participants With No FibrosisFazirsiran 200 mg: Participants With Fibrosis
Day 1, Pre-Dose0 ± 00 ± 00 ± 00 ± 00 ± 00 ± 0
Day 1, 1 hour (h)29.9 ± 75.650.6 ± 66.8190.0 ± 17.9173.0 ± 25.7495.0 ± 71.8356.0 ± 75.9
Day 1, 2h35.0 ± 83.060.7 ± 72.5208.0 ± 11.6199.0 ± 32.2537.0 ± 81.9471.0 ± 56.5
Day 1, 24h9.92 ± 99.66.33 ± 176.069.0 ± 88.426.6 ± 59.111.7 ± 1710027.7 ± 612.0
Week 16, Pre-Dose0 ± 00 ± 00 ± 00 ± 00 ± 00 ± 0
Week 16, 1h—38.1 ± 75.3—38.1 ± 75.3—396.0 ± 64.9
Week 16, 2h—45.1 ± 70.1—45.1 ± 70.1—487.0 ± 62.5
Week 16, 24h—3.64 ± 123.0—3.64 ± 123.0—104.0 ± 26.2
SecondaryNumber of Participants Positive for Anti-Drug Antibodies to Fazirsiran

PDLB=post-dose liver biopsy

Time frame:
Baseline, Weeks 4, 16, 28, 40, 48, 52, 64, 76, 88, 96, 100, 112, 124, 136, 148 or Early Termination (up to 148 weeks)
Reported as:
Count of participants · Participants
Number of Participants Positive for Anti-Drug Antibodies to Fazirsiran
ParticipantsFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mg
Baseline022
Week 4012
Week 16012
Week 28021
Week 40022
PDLB at Week 480—0
Week 52010
Week 64000
Week 76010
Week 88000
PDLB at Week 96——0
Week 100000
Week 112001
Week 124—01
Week 136——1
Week 148——1
Early Termination——0
SecondaryPercentage of Participants With Shifts From Baseline in METAVIR Fibrosis Stage at Post-Dose Biopsy for Participants With Fibrosis

The METAVIR scoring system is a system used to assess the extent of inflammation and fibrosis by histopathological evaluation in a liver biopsy. The stage represents the amount of fibrosis or scarring: 0= no fibrosis; 1=portal fibrosis without septa; 2=portal fibrosis with few septa; 3=numerous septa without cirrhosis; 4=cirrhosis. A higher score indicates a worse condition.

Time frame:
Baseline, Post-dose at Weeks 48 (+/- 2 weeks) or Week 72 (+/- 4 weeks) or Week 96 (+/- 4 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Shifts From Baseline in METAVIR Fibrosis Stage at Post-Dose Biopsy for Participants With Fibrosis
percentage of participantsFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlacebo
>= 1-point improvement from baseline66.740.050.037.5
no change from baseline25.060.014.344.4
>= 1-point worsening from baseline25.00.042.922.2

Adverse events

Collected over Participants without fibrosis: for a maximum duration of follow up of 66 weeks. Participants with evidence of fibrosis: for a maximum duration of follow up of 210 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fazirsiran 25 mg0/9 (0%)0/9 (0%)9/9 (100%)
Fazirsiran 100 mg0/8 (0%)0/8 (0%)8/8 (100%)
Fazirsiran 200 mg0/9 (0%)2/9 (22.2%)9/9 (100%)
Placebo0/14 (0%)3/14 (21.4%)14/14 (100%)
Fazirsiran 25 mg DB/200 mg OL0/4 (0%)1/4 (25%)4/4 (100%)
Fazirsiran 100 mg DB/200 mg OL0/5 (0%)1/5 (20%)4/5 (80%)
Fazirsiran 200 mg DB/200 mg OL0/5 (0%)1/5 (20%)3/5 (60%)
Placebo DB / Fazirsiran 200 mg OL0/9 (0%)1/9 (11.1%)9/9 (100%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlaceboFazirsiran 25 mg DB/200 mg OLFazirsiran 100 mg DB/200 mg OLFazirsiran 200 mg DB/200 mg OLPlacebo DB / Fazirsiran 200 mg OL
Pancreatitis acuteGastrointestinal disorders0/90/80/91/141/41/51/51/9
HaemoptysisRespiratory, thoracic and mediastinal disorders0/90/80/90/141/40/50/50/9
Pulmonary haemorrhageRespiratory, thoracic and mediastinal disorders0/90/80/90/141/40/50/50/9
Infective exacerbation of bronchiectasisInfections and infestations0/90/82/90/140/40/50/50/9
Clostridium difficile infectionInfections and infestations0/90/80/90/140/40/51/50/9
Pituitary tumour benignNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/90/80/90/140/41/50/50/9
Post procedural haemorrhageInjury, poisoning and procedural complications0/90/81/90/140/40/50/50/9
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/90/80/90/140/40/50/51/9
InfluenzaInfections and infestations0/90/80/91/140/40/50/50/9
Wound infection staphylococcalInfections and infestations0/90/80/91/140/40/50/50/9
Most frequent other events
Showing 10 of 200
Most frequent other events
EventFazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlaceboFazirsiran 25 mg DB/200 mg OLFazirsiran 100 mg DB/200 mg OLFazirsiran 200 mg DB/200 mg OLPlacebo DB / Fazirsiran 200 mg OL
COVID-19Infections and infestations0/92/87/92/140/41/51/52/9
HeadacheNervous system disorders4/91/82/94/140/42/50/50/9
NauseaGastrointestinal disorders1/90/81/93/140/42/50/51/9
Procedural painInjury, poisoning and procedural complications2/92/83/93/140/40/50/50/9
PalpitationsCardiac disorders0/92/80/90/140/40/50/50/9
Ear discomfortEar and labyrinth disorders0/90/80/90/141/40/50/50/9
Ear painEar and labyrinth disorders0/90/80/90/141/40/50/50/9
Abdominal pain upperGastrointestinal disorders0/92/80/90/140/40/50/50/9
FatigueGeneral disorders1/91/80/92/141/41/50/50/9
Injection site erythemaGeneral disorders0/91/80/92/141/40/50/50/9

Baseline characteristics

Age, Continuous
Age, Continuous(years)Fazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlaceboTotal
Mean52.6 ± 15.5647.9 ± 12.2551.6 ± 9.4457.4 ± 9.0553.1 ± 12.33
Sex: Female, Male
Sex: Female, Male(Participants)Fazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlaceboTotal
Female566522
Male423918
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Fazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlaceboTotal
Hispanic or Latino01023
Not Hispanic or Latino9791237
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Fazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlaceboTotal
White9891440
Fibrosis Status at Screening
Fibrosis Status at Screening(Participants)Fazirsiran 25 mgFazirsiran 100 mgFazirsiran 200 mgPlaceboTotal
Fibrosis at Screening457925
No fibrosis at Screening532515
08

Study locations

21 sites
  • Research Site 5
    Birmingham, Alabama 35233, United States
  • Research Site 9
    Phoenix, Arizona 85054, United States
  • Research Site 14
    La Jolla, California 92037, United States
  • Research Site 17
    Los Angeles, California 90095, United States
  • Research Site 11
    Sacramento, California 95817, United States
  • Research Site 15
    San Francisco, California 94158, United States
  • Research Site 13
    Stanford, California 94305, United States
  • Research Site 2
    Gainesville, Florida 32610, United States
  • Research Site 7
    Indianapolis, Indiana 46202, United States
  • Research Site 3
    Iowa City, Iowa 52242, United States
  • Research Site 10
    St Louis, Missouri 63104, United States
  • Research Site 12
    New York, New York 10032, United States
  • Research Site 1
    Charleston, South Carolina 29425, United States
  • Research Site 4
    Nashville, Tennessee 37232, United States
  • Research Site 19
    Houston, Texas 77030, United States
  • Research Site 16
    Salt Lake City, Utah 84132, United States
  • Research Site 27
    Aachen, 52074, Germany
  • Research Site 22
    Pavia, 27100, Italy
  • Research Site 23
    Leiden, 2333 ZA, Netherlands
  • Research Site 24
    Funchal, 9004-514, Portugal
  • Research Site 20
    Barcelona, 08035, Spain
09

References and documents

Publications

  • Clark VC, Strange C, Strnad P, Sanchez AJ, Kwo P, Pereira VM, van Hoek B, Barjaktarevic I, Corsico AG, Pons M, Goldklang M, Gray M, Kuhn B, Vargas HE, Vierling JM, Vuppalanchi R, Brantly M, Kappe N, Chang T, Schluep T, Zhou R, Hamilton J, San Martin J, Loomba R. Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA). Gastroenterology. 2024 Oct;167(5):1008-1018.e5. doi: 10.1053/j.gastro.2024.06.028. Epub 2024 Jul 2. PubMed 38964420 ↗
  • Remih K, Amzou S, Strnad P. Alpha1-antitrypsin deficiency: New therapies on the horizon. Curr Opin Pharmacol. 2021 Aug;59:149-156. doi: 10.1016/j.coph.2021.06.001. Epub 2021 Jul 10. PubMed 34256305 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Nov 2021, 27 months.

Results were first posted in Dec 2024, 3 years 1 month after primary completion. A results delay was requested in Oct 2022.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2019
First posted
May 10, 2019
StartActual
Aug 7, 2019
Primary completionActual
Nov 8, 2021
CompletionActual
Sep 18, 2023
Results delay requested
Oct 28, 2022
Results first posted
Dec 30, 2024
Last update
Nov 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03945292
Responsible party
Sponsor
First posted
May 10, 2019
Start date
Aug 7, 2019
Primary completion
Nov 8, 2021
Completion
Sep 18, 2023
Results posted
Dec 30, 2024
Last update
Nov 4, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fazirsiran

Start the discussion